Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760604 | 1.00 | NOTUM (0.62) | NOTUMTP53NPC1ALDH1A1LMNA | |
| SCHEMBL10384346 | 0.81 | ALDH1A1 (0.47) | NOTUMTP53ALDH1A1LMNAPKM | |
| SCHEMBL1760583 | 0.80 | NOTUM (0.50) | NOTUMNPC1ALDH1A1LMNARAB9A | |
| SCHEMBL1760584 | 0.80 | NOTUM (0.50) | NOTUMTP53SMN1; SMN2HSD17B3 | |
| SCHEMBL1760639 | 0.77 | NOTUM (0.52) | NOTUMLMNAHSD17B3 | |
| SCHEMBL5523654 | 0.77 | NOTUM (1.00) | NOTUMNPC1ALDH1A1LMNAPKM | |
| SCHEMBL2586534 | 0.77 | NOTUM (1.00) | NOTUMNPC1ALDH1A1LMNAPKM | |
| SCHEMBL10167044 | 0.77 | NOTUM (1.00) | NOTUMNPC1ALDH1A1LMNAPKM | |
| SCHEMBL5523649 | 0.76 | NOTUM (0.68) | NOTUMNPC1ALDH1A1LMNAPKM | |
| SCHEMBL16350248 | 0.76 | NOTUM (0.68) | NOTUMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247432-B2 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-21 | — | — | US | disclosed |
| CN-101307046-B | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-08-15 | — | — | CN | disclosed |
| US-20110224255-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | BRESLIN HENRY JOSEPH | 2011-09-15 | — | — | US | disclosed |
| US-7947713-B2 | (3-(4-phenyl-1H-imidazol-2-yl)-1,2,3,4-tetrahydro-isoquinoline; inactivation of endogenous neuropeptides such as cholecystokinis; eating disorders, obesity, psychotic syndromes and associated psychiatric disorders; chemical intermediates coupling | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-05-24 | — | — | US | disclosed |
| CN-101307046-A | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-19 | — | — | CN | disclosed |
| US-20080108653-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | BRESLIN HENRY J | 2008-05-08 | — | — | US | disclosed |
| EP-1392291-B1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-05-30 | — | — | EP | disclosed |
| US-20060276509-A1 | Tripeptidyl peptidase inhibitors | BRESLIN HENRY J | 2006-12-07 | — | — | US | disclosed |
| US-7125891-B2 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-24 | — | — | US | disclosed |
| EP-1392291-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-03 | — | — | EP | disclosed |
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-19 | — | — | US | disclosed |
| WO-2002036116-A9 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002036116-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-10 | — | — | WO | disclosed |
| US-4912125-A | 2,3-dihydro-2-(4,5-dihydroimidazol-2-yl)-indoles for reducing intraocular pressure | CIBA-GEIGY CORPORATION (US) | 1990-03-27 | — | — | US | disclosed |
| US-4908376-A | 2,3-dihydro-2-(4,5-dihydroimidazol-2-yl)-indoles in composition form for reducing intraocular pressure | CIBA-GEIGY CORPORATION (US) | 1990-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | NOTUM 1728/4885TP53 4834/4885NPC1 880/4885 |
| US-20080108653-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | CCKAR, CCKBR, VIP | NOTUM 1373/4885TP53 4662/4885NPC1 1258/4885 |
| US-20110224255-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | CCKAR, CCKBR, VIP | NOTUM 1373/4885TP53 4662/4885NPC1 1258/4885 |
| US-20060276509-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | NOTUM 1373/4885TP53 4662/4885NPC1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.